For the Inventor, By the Inventor

Enter assignee name

Frankfurt, Germany

Aventis Pharma Deutschland, Gmbh

Calculating rank

USPTO Granted Patents = 330

% Expired Patents = 13.9

CIPO Patents = 2

EPO Patents = 1

Trademarks = 5

Forward Citations = 3,463

Loading Chart...

Loading Chart...

433 inventors (with patents filed for the assignee):

Martin Bickel (29 out of 65 patents)

Gerhard Jaehne (25 out of 59 patents)

Hans-Jochen Lang (22 out of 108 patents)

4. Heiner Glombik (22 out of 75 patents)

5. Heinz-Werner Kleemann (20 out of 103 patents)

6. Hartmut Strobel (18 out of 54 patents)

7. Matthias Gossel (18 out of 46 patents)

8. Wendelin Frick (16 out of 49 patents)

9. Hans Jochen Lang (16 out of 43 patents)

10. Michael Kurz (15 out of 25 patents)

11. Karl Geisen (15 out of 34 patents)

12. Miles Hawley (15 out of 18 patents)

13. Joachim Brendel (14 out of 55 patents)

14. Ursula Schindler (14 out of 36 patents)

15. Wilfried Schwab (13 out of 47 patents)

Core Competencies:

Recombinant Glycoprotein

Heterocycles

Peptide Compounds

Tumor Antigens

Antimycotic Gel

Insulin Preparations

Oligonucleotides

Obesity Treatment

Cation Channels

Collagenase Inhibitors

Medical Devices

Angiotensin Inhibitors

330 patents: Sort by Forward Citations

1. 8278430 - Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use (2012-10-02),

2. 8198030 - Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use (2012-06-12),

3. 8048901 - 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as pharmaceuticals (2011-11-01),

4. 7968550 - Substituted N-aryl heterocycles, process for their preparation and their use as medicaments (2011-06-28),

5. 7928066 - Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use (2011-04-19),

6. 7662383 - Chimeric antibody against tumor associated antigens and its use in diagnosing tumors (2010-02-16),

7. 7300950 - Pyrazole derivatives, their preparation and their use in pharmaceuticals (2007-11-27),

8. 7166572 - Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical (2007-01-23),

9. 7049341 - N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use (2006-05-23),

10. 7045649 - C2-substituted idan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals (2006-05-16),

11. D520636 - Medical device for injecting fluid medicaments (2006-05-09),

12. 7026337 - Antimycotic gel having high active compound release (2006-04-11),

13. 7019028 - Endiandric acid H and its derivatives, process for their preparation and use thereof (2006-03-28),

14. 7019023 - Benzothiepine 1, 1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use (2006-03-28),

15. 7018656 - Antimycotic gel with high active substance release (2006-03-28),

Company Overview

Aventis Pharma Deutschland, GmbH, based in Frankfurt, specializes in pharmaceutical research and development, focusing on innovative therapeutic solutions. The company is recognized for its expertise in recombinant glycoproteins, heterocycles, and peptide compounds, contributing significantly to advancements in tumor antigens and obesity treatment. Additionally, Aventis develops antimyotic gels and insulin preparations, positioning itself as a key player in the pharmaceutical industry, dedicated to improving patient outcomes through cutting-edge research.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

330 Patents

#13 in Frankfurt

#179 in Germany

#2,735 in the World

Frankfurt, Germany

Aventis Pharma Deutschland, Gmbh

Forward Citations = 3,463

433 inventors:

Martin Bickel (29 out of 65 patents)

Gerhard Jaehne (25 out of 59 patents)

Hans-Jochen Lang (22 out of 108 patents)

4. Heiner Glombik (22 out of 75 patents)

5. Heinz-Werner Kleemann (20 out of 103 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aventis Pharma Deutschland, Gmbh. Retrieved from https://idiyas.com/company/aventis-pharma-deutschland

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…